The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication (Acute Repetitive Clusters, Anaphylaxis, COVID-19, Dry Eye Disease, Hypoglycemia, Influenza, Major Depressive Disorder, Migraine, Nasal Polyps and Prader-Willi Syndrome), Type of Molecule (Biologics and Small Molecule) and Geography (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    February 2022

  • Pages
    252

  • View Count
    736

Example Insights

Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Context Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Therapeutic-Candidates Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Phase-of-Development Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Trial-Analysis
Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Health-Indexing Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Delivery-Systems Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Competitiveness-Analysis Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Patent-Analysis
Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Partnerships-and-Collaborations Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Funding-and-Investments Intransal-Therapeutics-and-Drug-Delivery-Systems-Market-Forecast-and-Opportunity  

 

Overview

Over the past few years, the prevalence of neurological disorders has increased at an annualized rate of 10.9%. Further, the mortality associated with such diseases is projected to account for 12.2% of the global death rate, in 2030. In this context, several research initiatives are underway to identify an approach that allows effective delivery of the target medication directly into the brain. One key challenge currently faced by researchers is the presence of the complex blood brain barrier (BBB), which hinders the entry of the target drug into the CNS, acting as a significant roadblock in the development of effective treatment modalities. It is worth mentioning that the failure of the ongoing research initiatives can incur losses worth USD 2 billion. As a result, stakeholders in the pharmaceutical domain have shifted their focus towards the use of intranasal treatments, which have demonstrated to be capable of bypassing the blood brain barrier, thereby, delivering the target drug directly into the brain. Clinical studies related to interventional intranasal therapies have increased three-folds over the last decade. Specifically, post the onset of the COVID-19 pandemic, extensive research focused on intranasal therapeutics is being carried out due to their proven pharmacological value and favorable safety profiles. Notable examples of intranasal COVID-19 targeting drugs that are currently being evaluated across different phases of development include (in alphabetical order) COVIDROPS™ (Sorrento Therapeutics), DEXANEUROSONE™ (Biomed Industries™)  and Zavegepant (Biohaven Pharmaceuticals) . 

Despite the several advantages offered by the intranasal route of administration, the delivery of therapies via the aforementioned approach is associated with some challenges, such as mucus and epithelial barriers, low bioavailability of drugs, limited drug absorption and shorter residence time. Most of these concerns can be mitigated via the use of appropriate drug delivery systems. Therefore, several pharmaceutical companies are currently focused on the development of novel drug delivery systems for intranasal therapeutics, since conventional pharmaceutical dosage forms are unable to regulate the rate at which these drugs are delivered to the target site. At present, close to 40 intranasal drug delivery systems are available in the market. Additionally, USD 5.5 billion was invested in this domain, during 2016-2021. In the same time frame, multiple partnership agreements were established between various stakeholders. Driven by the increasing patient population and the growing demand for such therapeutics, this market is anticipated to witness steady growth in the coming years.

Scope of the Report

The “Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication (Acute Repetitive Clusters, Anaphylaxis, COVID-19, Dry Eye Disease, Hypoglycemia, Influenza, Major Depressive Disorder, Migraine, Nasal Polyps and Prader-Willi Syndrome), Type of Molecule (Biologics and Small Molecule) and Geography (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the likely future potential associated with the intranasal therapeutics and drug delivery systems market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in providing intranasal drug delivery systems, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of dosage form (liquid, powder and spray) and type of system (unit dose, multi dose and metered dose).
  • A detailed overview of the overall market landscape of players engaged in providing intranasal therapeutics, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, phase of development (phase I, phase II, Phase II/III, Phase III and Approved), type of molecule (biologics and small molecule) and therapeutic area (cardiovascular disorders, ear disorders, genetic disorders, infectious disorders, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, ophthalmic disorders, respiratory disorders and other disorders)
  • An in-depth company competitiveness analysis of intranasal drug delivery system providers based on company strength (in terms of experience and company size), and product portfolio strength (such as number of products, type of dosage form, type of system and volume range).
  • An in-depth analysis of completed, ongoing and planned clinical trials focused on intranasal therapeutics, based on several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target indication, most popular indications and key geographical regions.
  • An analysis of the recent partnerships inked between various players engaged in the development of intranasal therapeutics, during the period 2016-2021. Additionally, it includes a brief description of the various types of partnership models (such as service agreements, licensing agreements (specific to affiliated technology platforms and product candidates), technology utilization agreements, product manufacturing agreements, product development and commercialization agreements, clinical trial agreements) that have been adopted by stakeholders engaged in this domain.
  • A detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by players engaged in this domain, during the period 2016-2021.
  • An analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in this domain, based on several parameters, such as number of candidates in discovery, preclinical and clinical phases of development, number of partnerships, number of patents, amount raised, number of investors, types of funding and number of deals inked.
  • An in-depth analysis of patents related to intranasal therapeutics and drug delivery systems, filed / granted, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of applicant, and leading players (in terms of number of patents). In addition, it features a patent valuation analysis, highlighting the qualitative and quantitative aspects of patents.
  • A detailed discussion on the various steps of the supply chain model, namely concept of development & proof of concept, research and development, regulatory approvals and marketing and sales of the intranasal drug delivery systems and the cost requirements across each of the aforementioned stages.

One of the key objectives of the report was to evaluate the current opportunity and future growth potential within the intranasal therapeutics and drug delivery systems market, over the next decade. We have also provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, over the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] target indication (acute repetitive clusters, anaphylaxis, COVID-19, dry eye disease, hypoglycemia, influenza, major depressive disorder, migraine, nasal polyps and prader-willi syndrome), [B] type of molecule (biologics and small molecules) and [C] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).  In order to account for future uncertainties and add robustness to our forecast model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in the development of intranasal therapeutics and drug delivery systems?
  • What are the major therapeutic areas targeted by intranasal therapeutics?
  • Which regions represent the maximum research activity related to intranasal therapeutics and drug delivery systems?
  • What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
  • Who are the key investigators in this domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to intranasal therapeutics and drug delivery systems?

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of the intranasal therapeutics and drug delivery systems market and its likely evolution in the mid to long-term. 

Chapter 3 provides a general introduction to history of intranasal drugs, featuring insights on mechanism of action of intranasal therapeutics. It further includes a brief introduction to intranasal therapeutics and drug delivery systems, along with information on the mechanism of intranasal drug delivery. Further, it highlights key challenges associated with this domain. 

Chapter 4 features a detailed overview of the overall market landscape of players engaged in providing intranasal drug delivery systems, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of dosage form (liquid, powder and spray) and type of system (unit dose, multi dose and metered dose).   

Chapter 5 provides a detailed overview of the overall market landscape of players engaged in providing intranasal therapeutics, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, phase of development (phase I, phase II, Phase II/III, Phase III and Approved), type of molecule (biologics and small molecule) and therapeutic area (cardiovascular disorders, ear disorders, genetic disorders, infectious disorders, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, ophthalmic disorders, respiratory disorders and other disorders)  

Chapter 6 features an in-depth company competitiveness analysis of intranasal drug delivery systems providers based on company strength (in terms of experience and company size), and product portfolio strength (such as number of products, type of dosage form, type of system and volume range)

Chapter 7 features an in-depth analysis of completed, ongoing and planned clinical trials focused on intranasal therapeutics, based on several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target indication, most popular indications and key geographical regions

Chapter 8 features detailed profiles of the key stakeholders involved in the development of intranasal drug delivery systems. Each profile features a brief overview of the company, its financial information, details on its product portfolio, and recent developments and an informed future outlook.

Chapter 9 provides detailed profiles of phase II / III, phase III and approved intranasal therapeutics. Each drug profile provides information on their current development status, route of administration, primary target indication, dosage, mechanism of action, clinical trials, clinical trial results, collaborations and special drug designation(s) received (if any).

Chapter 10 features an analysis of the recent partnerships inked between various players engaged in the development of intranasal therapeutics, during the period 2016-2021. Additionally, it includes a brief description of the various types of partnership models (such as service agreements, licensing agreements (specific to affiliated technology platforms and product candidates), technology utilization agreements, product manufacturing agreements, product development and commercialization agreements, clinical trial agreements) that have been adopted by stakeholders engaged in this domain

Chapter 11 features a detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by engaged in this domain, during the period 2016-2021.

Chapter 12 features an analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in this domain, based on several parameters, such as number of candidates in discovery, preclinical and clinical phases of development, number of partnerships, number of patents, amount raised, number of investors, types of funding and number of deals inked

Chapter 13 provides an in-depth analysis of patents related to intranasal therapeutics and drug delivery systems, filed / granted, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of applicant, and leading players (in terms of number of patents). In addition, it features a patent valuation analysis, highlighting the qualitative and quantitative aspects of patents

Chapter 14 features a detailed discussion on the various steps of the supply chain model, namely concept of development & proof of concept, research and development, regulatory approvals and marketing and sales of the intranasal drug delivery systems and the cost requirements across each of the aforementioned stages

Chapter 15 presents an insightful market forecast analysis, highlighting the future potential of intranasal therapeutics and drug delivery systems, till 2035. We have segmented the market on the basis of [A] target indication (acute repetitive clusters, anaphylaxis, COVID-19, dry eye disease, hypoglycemia, influenza, major depressive disorder, migraine, nasal polyps and prader-willi syndrome), [B] type of molecule (biologics and small molecule) and [C] geography (North America, Europe, Asia-Pacific, and Rest of the World).

Chapter 16 is a collection of interview transcripts; these discussions were held with key stakeholders in the industry.

Chapter 17 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the intranasal therapeutics and drug delivery systems market.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report. 

Chapter 19 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Intranasal Therapies

3.3. Mechanism of Intranasal Drug Delivery
3.3.1. Intracellular Pathway
3.3.2. Extracellular Pathway

3.4. Types of Intranasal Drug Formulations

3.5. Types of Intranasal Drug Delivery Systems
3.5.1. Droppers
3.5.2. Unit / Bi-dose Systems
3.5.3. Spray Tips
3.5.4. Dry powder Systems
3.5.5. Multi-dose Systems

3.6. Regulatory Landscape for Intranasal Therapies
3.7. Future Perspectives

4. MARKET LANDSCAPE (DRUG DELIVERY SYSTEMS)
4.1. Chapter Overview
4.2. Intranasal Drug Delivery Systems: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis By Year of Establishment, Company Size and Location of Headquarters
4.2.5. Most Active Players: Analysis by Number of Products

4.3. Intranasal Drug Delivery Systems: Product Landscape
4.3.1. Analysis by Type of Dosage Form
4.3.2. Analysis by Type of System
4.3.3. Analysis by Dosage Volume Range

5. MARKET LANDSCAPE (DRUG PIPELINE)
5.1. Chapter Overview
5.2. Intranasal Therapeutics: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarter
5.2.5. Most Active Players: Analysis by Number of Therapeutics

5.3. Intranasal Therapeutics: Pipeline Review
5.3.1. Analysis by Phase of Development
5.3.2. Analysis by Type of Molecule
5.3.3. Analysis by Target Therapeutic Area
5.3.4. Analysis by Type of Molecule and Phase of Development
5.3.5. Analysis by Type of Molecule and Company Size
5.3.6. Most Active Players: Analysis by Phase of Development

6. COMPANY COMPETITIVENESS ANALYSIS (DRUG DELIVERY SYSTEMS)
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.3.1. Company Competitiveness Analysis: Drug Delivery Systems

6.4. Company Competitiveness: Benchmarking the Capabilities of Leading Players

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology

7.3. Intranasal therapeutics: Clinical Trials Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Phase
7.3.4. Analysis by Trial Registration Year and Trial Status
7.3.5. Analysis by Enrolled Patient Population and Trial Phase
7.3.6. Analysis by Type of Sponsor / Collaborator
7.3.7. Analysis by Target Patient Group
7.3.8. Analysis by Target Therapeutic Area
7.3.9. Analysis by Study Design
7.3.10. Most Active Players: Analysis by Number of Registered Trials
7.3.11. Analysis by Number of Trials and Geographical Location
7.3.12. Analysis by Number of Trials, Trial Status and Geographical Location
7.3.13. Analysis by Enrolled Patient Population, Trial Status and Geographical Location

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Aptar Pharma
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Product Portfolio
8.2.4. Recent Developments and Future Outlook

8.3. Nemera
8.3.1. Company Overview
8.3.2. Product Portfolio
8.3.3. Recent Developments and Future Outlook

8.4. Teleflex
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Product Portfolio
8.4.4. Recent Development and Future Outlook

8.5. Mystic Pharmaceuticals
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.3. Recent Development and Future Outlook

8.6. Zeteo Medical
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.3. Recent development and Future Outlook

9. DRUG PROFILES
9.1 Chapter Overview
9.2. TrudhesaTM
9.3. Tyrvaya
9.4. VALTOCO®
9.5. SPRAVATO®
9.6. BAQSIMITM
9.7. NAYZILAM®
9.8. Tosymra®
9.9. XHANCETM
9.10. SINUVA
9.11. NeffyTM
9.12. ZAVEGEPANT (BHV-3500)
9.13. LV-101
9.14. MEDI3250
9.15. DEXANEUROSONE™

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Intranasal Therapeutics and Drug Delivery Systems: Recent Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Focus Area
10.3.5. Analysis by Therapeutic Area

10.4. Most Active Players: Analysis by Number of Partnerships

10.5. Analysis by Geography
10.5.1. Country-wise Distribution
10.5.2. Intercontinental and Intracontinental Distribution

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2 Types of Funding

11.3. Intranasal Therapeutics and Drug Delivery Systems: Funding and Investments
11.3.1. Analysis of Number of Funding Instances by Year
11.3.2. Analysis of Amount Invested by Year
11.3.3. Analysis by Number of funding Instances and Type of Funding
11.3.4. Analysis by Amount Invested and Type of Funding
11.3.5. Analysis by Year and Type of Funding
11.3.6. Analysis by Focus Area and Amount Invested
11.3.7. Analysis by Therapeutic Area and Amount Invested
11.3.8. Analysis by Type of Molecule and Amount Invested
11.3.9. Analysis by Geography
11.3.10. Most Active Players: Analysis by Number of Funding Instances
11.3.11. Most Active Investors: Analysis by Amount Invested

11.4. Concluding Remarks

12. START-UP HEALTH INDEXING (DRUG PIPELINE)
12.1. Chapter Overview
12.2. Start-ups in Intranasal Therapeutics
12.2.1. Analysis by Location of Headquarters

12.3. Benchmarking of Start-ups

12.4. Startup-Health Indexing
12.4.1. Analysis by Supplier Strength
12.4.1. Analysis by Pipeline Strength
12.4.2. Analysis by Pipeline Maturity
12.4.4. Analysis by Financial Investments
12.4.5. Analysis by Partnership Activity
12.4.6. Start-ups Health Indexing: Roots Analysis Perspective

13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology

13.3. Intranasal Therapeutics and Drug Delivery Systems: Patent Analysis
13.3.1. Analysis by Publication Year
13.3.2. Analysis by Geography
13.3.3. Analysis by CPC Symbols
13.3.4. Emerging Focus Areas
13.3.5. Analysis by Type of Applicant
13.3.6. Leading Players: Analysis by Number of Patents

13.4. Intranasal Therapeutics and Drug Delivery Systems: Patent Valuation Analysis
13.5. Leading Patents: Analysis by Number of Citations

14. VALUE CHAIN ANALYSIS
14.1. Chapter Overview
14.2. Intranasal Drug Delivery Devices Value Chain

14.3. Cost Distribution Across the Value Chain
14.3.1. Costs Associated with Concept Development and Proof of Concept
14.3.2. Costs Associated with Research and Development
14.3.3. Costs Associated with Regulatory Approvals
14.3.4. Costs Associated Marketing and Sales

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Key Assumptions and Forecast Methodology

15.4. Global Intranasal Therapeutics and Drug Delivery Systems Market, 2022-2035
15.5. Global Intranasal Therapeutics and Drug Delivery Systems Market: Analysis by Target Indication, 2022 and 2035
15.6. Global Intranasal Therapeutics and Drug Delivery Systems Market: Analysis by Type of Molecule, 2022 and 2035
15.7. Global Intranasal Therapeutics and Drug Delivery Systems Market: Analysis by Key Players, 2022 and 2035
15.8. Global Intranasal Therapeutics and Drug Delivery Systems Market: Analysis by Geography, 2022 and 2035

15.9. Intranasal Therapeutics and Drug Delivery Systems: Product-wise Sales Forecast
15.9.1. TRUDHESA (Impel NeuroPharma)
15.9.1.1. Target Patient Population
15.9.1.2. Sales Forecast
15.9.1.3. Net Present Value

15.9.2. VALTOCO (Neurelis)
15.9.2.1. Target Patient Population
15.9.2.2. Sales Forecast
15.9.2.3. Net Present Value

15.9.3. Tyrvaya (Oyster Point Pharma)
15.9.3.1. Target Patient Population
15.9.3.2. Sales Forecast
15.9.3.3. Net Present Value

15.9.4. SPRAVATO (Janssen Pharmaceuticals)
15.9.4.1. Target Patient Population
15.9.4.2. Sales Forecast
15.9.4.3. Net Present Value

15.9.5. BAQSIMI (Eli Lilly)
15.9.5.1. Target Patient Population
15.9.5.2. Sales Forecast
15.9.5.3. Net Present Value

15.9.6. NAYZILAM (UCB)
15.9.6.1. Target Patient Population
15.9.6.2. Sales Forecast
15.9.6.3. Net Present Value

15.9.7. Tosymra (Dr. Reddy’s Laboratories)
15.9.7.1. Target Patient Population
15.9.7.2. Sales Forecast
15.9.7.3. Net Present Value

15.9.8. XHANCE (OptiNose)
15.9.8.1. Target Patient Population
15.9.8.2. Sales Forecast
15.9.8.3. Net Present Value

15.9.9. ONZETRA Xsail (OptiNose)
15.9.9.1. Target Patient Population
15.9.9.2. Sales Forecast
15.9.9.3. Net Present Value

15.9.10. SINUVA (Intersect ENT)
15.9.10.1. Target Patient Population
15.9.10.2. Sales Forecast
15.9.10.3. Net Present Value

15.9.11. Neffy (ARS Pharmaceuticals)
15.9.11.1. Target Patient Population
15.9.11.2. Sales Forecast
15.9.11.3. Net Present Value

15.9.12. MEDI3250 (Daiichi Sankyo)
15.9.12.1. Target Patient Population
15.9.12.2. Sales Forecast
15.9.12.3. Net Present Value

15.9.13. BHV3500 (Biohaven Pharmaceuticals)
15.9.13.1. Target Patient Population
15.9.13.2. Sales Forecast
15.9.13.3. Net Present Value

15.9.14. LV-101 (Levo Therapeutics)
15.9.14.1. Target Patient Population
15.9.14.2. Sales Forecast
15.9.14.3. Net Present Value

15.9.15. BHV-3500 (Biohaven Pharmaceuticals)
15.9.15.1. Target Patient Population
15.9.15.2. Sales Forecast
15.9.15.3. Net Present Value

15.9.16. DEXANEUROSONE (Biomed Industries)
15.9.16.1. Target Patient Population
15.9.16.2. Sales Forecast
15.9.16.3. Net Present Value

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview

17. CONCLUDING REMARKS
18. APPENDIX I: TABULATED DATA
19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 2.1 Executive Summary: Current Market Landscape of Intranasal Drug Delivery Systems
Figure 2.2 Executive Summary: Current Market Landscape of Intranasal Therapeutics
Figure 2.3 Executive Summary: Company Competitiveness Analysis
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Partnerships and Collaborations
Figure 2.6 Executive Summary: Fundings and Investments
Figure 2.7 Executive Summary: Startup-Health Indexing
Figure 2.8 Executive Summary: Patent Analysis
Figure 2.9 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Intracellular Pathway of Intranasal Drug Delivery
Figure 3.2 Extracellular Pathway of Intranasal Drug Delivery
Figure 4.1 Intranasal Drug Delivery System Developers: Distribution by Year of Establishment
Figure 4.2 Intranasal Drug Delivery System Developers: Distribution by Company Size
Figure 4.3 Intranasal Drug Delivery System Developers: Distribution by Location of Headquarters
Figure 4.4 Intranasal Drug Delivery System Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 4.5 Most Active Players: Distribution by Number of Products
Figure 4.6 Intranasal Drug Delivery Systems: Distribution by Type of Dosage Form
Figure 4.7 Intranasal Drug Delivery Systems: Distribution by Type of System
Figure 4.8 Intranasal Drug Delivery Systems: Distribution by Range of Dosage Volume
Figure 5.1 Intranasal Therapeutic Developers: Distribution by Year of Establishment
Figure 5.2 Intranasal Therapeutic Developers: Distribution by Company Size
Figure 5.3 Intranasal Therapeutic Developers: Distribution by Location of Headquarters
Figure 5.4 Intranasal Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Figure 5.5 Most Active Players: Distribution by Number of Therapeutics
Figure 5.6 Intranasal Therapeutics: Distribution by Phase of Development
Figure 5.7 Intranasal Therapeutics: Distribution by Type of Molecule
Figure 5.8 Intranasal Therapeutics: Distribution by Target Therapeutic Area
Figure 5.9 Intranasal Therapeutics: Distribution by Type of Molecule and Phase of Development
Figure 5.10 Intranasal Therapeutics: Distribution by Type of Molecule and Company Size
Figure 5.11 Most Active Players: Distribution by Phase of Development
Figure 6.1 Company Competitiveness Analysis: Drug Delivery Systems
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.6 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.8 Clinical Trial Analysis: Distribution by Target Patient Group
Figure 7.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 7.10 Clinical Trial Analysis: Distribution by Study Design
Figure 7.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 7.12 Clinical Trial Analysis: Distribution by Number of Trials and Geographical Location
Figure 7.13 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
Figure 7.14 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
Figure 8.1 Aptar Pharma: Annual Revenues, 2017-9M 2021 (USD Billion)
Figure 8.2 Teleflex: Annual Revenues, 2017-9M 2021 (USD Billion)
Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership, 2016- 2021
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 10.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 10.6 Most Active Players: Distribution by Number of Partnerships
Figure 10.7 Partnerships and Collaborations: Distribution by Geography
Figure 10.8 Partnerships and Collaborations: Country-wise Distribution
Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 11.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
Figure 11.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), 2016-2021
Figure 11.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2016-2021
Figure 11.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million), 2016-2021
Figure 11.5 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding
Figure 11.6 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 11.7 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
Figure 11.8 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Figure 11.9 Funding and Investment Analysis: Distribution of Amount Invested by Type of Molecule (USD Million)
Figure 11.10 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, 2016-2021
Figure 11.11 Most Active Players: Distribution by Number of Funding Instances
Figure 11.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 11.13 Concluding Remarks
Figure 12.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 12.2 Startup-Health Indexing: Distribution by Supplier Strength
Figure 12.3 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 12.4 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 12.5 Startup-Health Indexing: Distribution by Financial Investments
Figure 12.6 Startup-Health Indexing: Distribution by Partnership Activity
Figure 12.7 Startup-Health Indexing: Roots Analysis Perspective
Figure 12.8 Spider Web Analysis: Leading Companies
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Distribution by Publication Year
Figure 13.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 13.4 Patent Analysis: Distribution by Geography
Figure 13.5 Patent Analysis: Distribution by Jurisdiction
Figure 13.6 Patent Analysis: Distribution by CPC Symbols
Figure 13.7 Patent Analysis: Emerging Focus Areas
Figure 13.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 13.9 Leading Industry Players: Distribution by Number of Patents
Figure 13.10 Patent Valuation Analysis: Distribution of Patents by Geography
Figure 13.11 Intranasal Therapeutics and Drug Delivery Systems: Patent Valuation
Figure 14.1 Value Chain Analysis: Intranasal Drug Delivery Devices
Figure 14.2 Cost Distribution Across Value Chain
Figure 14.3 Costs Associated with Concept Development and Proof of Concept
Figure 14.4 Costs Associated with Research and Development
Figure 14.5 Costs Associated with Regulatory Approvals
Figure 14.6 Costs Associated with Marketing and Sales
Figure 15.1 Global Intranasal Therapeutics and Drug Delivery Systems Market, 2022-2035 (USD Million)
Figure 15.2 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Target Indication, 2022 and 2035
Figure 15.3 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Type of Molecule, 2022 and 2035
Figure 15.4 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Key Players, 2022 and 2035
Figure 15.5 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Geography, 2022 and 2035
Figure 15.6 TRUDHESA (Impel NeuroPharma): Estimated Sales, 2022-2035 (USD Million)
Figure 15.7 VALTOCO (Neurelis): Estimated Sales, 2022-2035 (USD Million)
Figure 15.8 Tyrvaya (Oyster Point Pharma): Estimated Sales, 2022-2035 (USD Million)
Figure 15.9 SPRAVATO (Janssen Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 15.10 BAQSIMI (Eli Lilly): Estimated Sales, 2022-2035 (USD Million)
Figure 15.11 NAYZILAM (UCB): Estimated Sales, 2022-2035 (USD Million)
Figure 15.12 Tosymra (Dr. Reddy’s Laboratories): Estimated Sales, 2022-2035 (USD Million)
Figure 15.13 XHANCE (OptiNose): Estimated Sales, 2022-2035 (USD Million)
Figure 15.14 ONZETRA Xsail (OptiNose): Estimated Sales, 2022-2035 (USD Million)
Figure 15.15 SINUVA (Intersect ENT): Estimated Sales, 2022-2035 (USD Million)
Figure 15.16 Neffy (ARS Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 15.17 MEDI3250 (Daiichi Sankyo): Estimated Sales, 2022-2035 (USD Million)
Figure 15.18 BHV3500 (Biohaven Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 15.19 LV-101 (Levo Therapeutics): Estimated Sales, 2022-2035 (USD Million)
Figure 15.20 BHV-3500 (Biohaven Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 15.21 DEXANEUROSONE (Biomed Industries): Estimated Sales, 2022-2035 (USD Million)
Figure 17.1 Concluding Remarks: Current Market Landscape for Intranasal Drug Delivery Systems
Figure 17.2 Concluding Remarks: Current Market Landscape for Intranasal Therapeutics
Figure 17.3 Concluding Remarks: Company Competitiveness Analysis: Intranasal Drug Delivery Systems
Figure 17.4 Concluding Remarks: Clinical Trial Analysis
Figure 17.5 Concluding Remarks: Partnerships and Collaborations
Figure 17.6 Concluding Remarks: Fundings and Investments
Figure 17.7 Concluding Remarks: Startup-Health Indexing
Figure 17.8 Concluding Remarks: Patent Analysis
Figure 17.9 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Inhaled and Intranasal Products: Various Guidelines Issued by Regulatory Authorities
Table 4.1 List of Intranasal Drug Delivery System Developers
Table 4.2 List of Intranasal Drug Delivery Systems
Table 5.1 List of Intranasal Therapeutic Developers
Table 5.2 List of Intranasal Therapeutics
Table 6.1 Company Competitiveness: Benchmarking the Capabilities of Leading Players
Table 8.1 Aptar Pharma: Company Overview
Table 8.2 Aptar Pharma: Product Details
Table 8.3 Aptar Pharma: Recent Developments and Future Outlook
Table 8.4 Nemera: Company Overview
Table 8.5 Nemera: Product Details
Table 8.6 Nemera: Future Outlook
Table 8.7 Teleflex: Company Overview
Table 8.8 Teleflex: Product Details
Table 8.9 Teleflex: Future Outlook
Table 8.10 Mystic Pharmaceuticals: Company Overview
Table 8.11 Mystic Pharmaceuticals: Product Details
Table 8.12 Zeteo Biomedical: Company Overview
Table 8.13 Zeteo Biomedical: Product Details
Table 8.14 Zeteo Biomedical: Future Outlook
Table 9.1 Intranasal Therapeutics: List of Drugs
Table 9.2 Drug Profile: Trudhesa (Overview of Drug, Current Development Status and Clinical Results)
Table 9.3 Drug Profile: Tyrvaya (Overview of Drug, Current Development Status and Clinical Results)
Table 9.4 Drug Profile: VALTOCO® (Overview of Drug, Current Development Status and Clinical Results)
Table 9.5 Drug Profile: SPRAVATO® (Overview of Drug, Current Development Status and Clinical Results)
Table 9.6 Drug Profile: BAQSIMITM (Overview of Drug, Current Development Status and Clinical Results)
Table 9.7 Drug Profile: NAYZILAM® (Overview of Drug, Current Development Status and Clinical Results)
Table 9.8 Drug Profile: Tosymra® (Overview of Drug, Current Development Status and Clinical Results)
Table 9.9 Drug Profile: XHANCETM (Overview of Drug, Current Development Status and Clinical Results)
Table 9.10 Drug Profile: SINUVA (Overview of Drug, Current Development Status and Clinical Results)
Table 9.11 Drug Profile: NeffyTM (Overview of Drug, Current Development Status and Clinical Results)
Table 9.12 Drug Profile: Zavegepant (BHV-3500) (Overview of Drug, Current Development Status and Clinical Results)
Table 9.13 Drug Profile: LV-101 (Overview of Drug, Current Development Status and Clinical Results)
Table 10.1 Partnerships and Collaborations: List of Partnerships and Collaborations, 2016-2021
Table 11.1 Intranasal Therapeutics and Drug Delivery Systems: List of Funding and Investment
Table 12.1 Intranasal Therapeutics Start-ups: Distribution by Location of Headquarters
Table 13.1 Patent Analysis: Prominent CPC Symbols
Table 13.2 Patent Analysis: Most Popular CPC Symbols
Table 13.3 Patent Analysis: List of Top CPC Symbols
Table 13.4 Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
Table 13.5 Patent Analysis: List of Relatively High Value Patents
Table 15.1 Intranasal Therapeutics: Expected Launch Years of Advanced Stage Drug Candidates
Table 15.2 TRUDHESA: Target Patient Population
Table 15.3 TRUDHESA: Net Present Value (USD Million)
Table 15.4 VALTOCO: Target Patient Population
Table 15.5 VALTOCO: Net Present Value (USD Million)
Table 15.6 Tyrvaya: Target Patient Population
Table 15.7 Tyrvaya: Net Present Value (USD Million)
Table 15.8 SPRAVATO: Target Patient Population
Table 15.9 SPRAVATO: Net Present Value (USD Million)
Table 15.10 BAQSIMI: Target Patient Population
Table 15.11 BAQSIMI: Net Present Value (USD Million)
Table 15.12 NAYZILAM: Target Patient Population
Table 15.13 NAYZILAM: Net Present Value (USD Million)
Table 15.14 Tosymra: Target Patient Population
Table 15.15 Tosymra: Net Present Value (USD Million)
Table 15.16 XHANCE: Target Patient Population
Table 15.17 XHANCE: Net Present Value (USD Million)
Table 15.18 ONZETRA Xsail: Target Patient Population
Table 15.19 ONZETRA Xsail: Net Present Value (USD Million)
Table 15.20 SINUVA: Target Patient Population
Table 15.21 SINUVA: Net Present Value (USD Million)
Table 15.22 Neffy: Target Patient Population
Table 15.23 Neffy: Net Present Value (USD Million)
Table 15.24 MEDI3250: Target Patient Population
Table 15.25 MEDI3250: Net Present Value (USD Million)
Table 15.26 BHV3500: Target Patient Population
Table 15.27 BHV3500: Net Present Value (USD Million)
Table 15.28 LV-101: Target Patient Population
Table 15.29 LV-101: Net Present Value (USD Million)
Table 15.30 BHV-3500: Target Patient Population
Table 15.31 BHV-3500: Net Present Value (USD Million)
Table 15.32 DEXANEUROSONE: Target Patient Population
Table 15.33 DEXANEUROSONE: Net Present Value (USD Million)
Table 18.1 Intranasal Drug Delivery System Developers: Distribution by Year of Establishment
Table 18.2 Intranasal Drug Delivery System Developers: Distribution by Company Size
Table 18.3 Intranasal Drug Delivery System Developers: Distribution by Location of Headquarters
Table 18.4 Intranasal Drug Delivery System Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 18.5 Most Active Players: Distribution by Number of Products
Table 18.6 Intranasal Drug Delivery Systems: Distribution by Type of Dosage Form
Table 18.7 Intranasal Drug Delivery Systems: Distribution by Type of System
Table 18.8 Intranasal Drug Delivery Systems: Distribution by Range of Dosage Volume
Table 18.9 Intranasal Therapeutic Developers: Distribution by Year of Establishment
Table 18.10 Intranasal Therapeutic Developers: Distribution by Company Size
Table 18.11 Intranasal Therapeutic Developers: Distribution by Location of Headquarters
Table 18.12 Intranasal Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Table 18.13 Most Active Players: Distribution by Number of Therapeutics
Table 18.14 Intranasal Therapeutics: Distribution by Phase of Development
Table 18.15 Intranasal Therapeutics: Distribution by Type of Molecule
Table 18.16 Intranasal Therapeutics: Distribution by Target Therapeutic Area
Table 18.17 Intranasal Therapeutics: Distribution by Type of Molecule and Phase of Development
Table 18.18 Intranasal Therapeutics: Distribution by Type of Molecule and Company Size
Table 18.19 Most Active Players: Distribution by Phase of Development
Table 18.20 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 18.21 Clinical Trial Analysis: Distribution by Trial Status
Table 18.22 Clinical Trial Analysis: Distribution by Trial Phase
Table 18.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 18.24 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
Table 18.25 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 18.26 Clinical Trial Analysis: Distribution by Target Patient Group
Table 18.27 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 18.28 Clinical Trial Analysis: Distribution by Study Design
Table 18.29 Most Active Industry Players: Distribution by Number of Registered Trials
Table 18.30 Clinical Trial Analysis: Distribution by Number of Trials and Geographical Location
Table 18.31 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
Table 18.32 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
Table 18.33 Aptar Pharma: Annual Revenues, 2017-9M 2021 (USD Billion)
Table 18.34 Teleflex: Annual Revenues, 2017-9M 2021 (USD Billion)
Table 18.35 Partnerships and Collaborations: Distribution by Year of Partnership, 2016- 2021
Table 18.36 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.37 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 18.38 Partnerships and Collaborations: Distribution by Focus Area
Table 18.39 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 18.40 Most Active Players: Distribution by Number of Partnerships
Table 18.41 Partnerships and Collaborations: Distribution by Geography
Table 18.42 Partnerships and Collaborations: Country-wise Distribution
Table 18.43 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 18.44 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
Table 18.45 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), 2016-2021
Table 18.46 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2016-2021
Table 18.47 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million), 2016-2021
Table 18.48 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding
Table 18.49 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Table 18.50 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
Table 18.51 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Table 18.52 Funding and Investment Analysis: Distribution of Amount Invested by Type of Molecule (USD Million)
Table 18.53 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, 2016-2021
Table 18.54 Most Active Players: Distribution by Number of Funding Instances
Table 18.55 Most Active Players: Distribution by Amount Invested (USD Million)
Table 18.56 Startup-Health Indexing: Distribution by Location of Headquarters
Table 18.57 Startup-Health Indexing: Distribution by Supplier Strength
Table 18.58 Startup-Health Indexing: Distribution by Pipeline Strength
Table 18.59 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 18.60 Startup-Health Indexing: Distribution by Financial Investments
Table 18.61 Startup-Health Indexing: Distribution by Partnership Activity
Table 18.62 Patent Analysis: Distribution by Type of Patent
Table 18.63 Patent Analysis: Cumulative Distribution by Publication Year
Table 18.64 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 18.65 Patent Analysis: Distribution by Geography
Table 18.66 Patent Analysis: Distribution by Jurisdiction
Table 18.67 Patent Analysis: Distribution by CPC Symbols
Table 18.68 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 18.69 Leading Industry Players: Distribution by Number of Patents
Table 18.70 Patent Valuation Analysis: Distribution of Patents by Geography
Table 18.71 Intranasal Therapeutics and Drug Delivery Systems: Patent Valuation
Table 18.72 Global Intranasal Therapeutics and Drug Delivery Systems Market, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.73 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Target Indication, 2022 and 2035
Table 18.74 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Type of Molecule, 2022 and 2035
Table 18.75 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Key Players, 2022 and 2035
Table 18.76 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Geography, 2022 and 2035
Table 18.77 TRUDHESA (Impel NeuroPharma): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.78 VALTOCO (Neurelis): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.79 Tyrvaya (Oyster Point Pharma): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.80 SPRAVATO (Janssen Pharmaceuticals): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.81 BAQSIMI (Eli Lilly): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.82 NAYZILAM (UCB): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.83 Tosymra (Dr. Reddy’s Laboratories): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.84 XHANCE (OptiNose): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.85 ONZETRA Xsail (OptiNose): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.86 SINUVA (Intersect ENT): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.87 Neffy (ARS Pharmaceuticals): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.88 MEDI3250 (Daiichi Sankyo): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.89 BHV3500 (Biohaven Pharmaceuticals): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.90 LV-101 (Levo Therapeutics): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.91 BHV-3500 (Biohaven Pharmaceuticals): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.92 DEXANEUROSONE (Biomed Industries): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. Adapt Pharma
  2. Aegis Therapeutics
  3. AIM ImmunoTech
  4. AllianceRx Walgreens Prime
  5. Altamira Therapeutics
  6. Altimmune
  7. AOBiome Therapeutics
  8. Apricus Biosciences
  9. Aptar Pharma
  10. ARS Pharmaceuticals
  11. ATAI Life Sciences
  12. AViTA
  13. Baudax Bio
  14. BD
  15. Bespak
  16. Bharat Biotech
  17. Biohaven Pharmaceuticals
  18. Biomed Industries™
  19. BlueWillow Biologics®
  20. Bryn Pharma
  21. Camargo
  22. Centre for Human Drug Research
  23. Codagenix
  24. Consort Medical
  25. Copernicus
  26. Currax Pharmaceuticals
  27. Cyrano Therapeutics
  28. Daiichi Sankyo
  29. Dauntless Pharmaceuticals
  30. DeVilbiss Healthcare
  31. Dne Pharma
  32. Dr. Reddy’s Laboratories
  33. DynPort Vaccine Company
  34. Eli Lilly
  35. ENDECE
  36. Ferring Pharmaceuticals
  37. FHI Clinical
  38. Fiagon
  39. Glenmark Pharmaceuticals
  40. Grandpharma (China)
  41. HealthPartners Institute
  42. Hikma
  43. hVIVO
  44. IDC
  45. Impel NeuroPharma
  46. Inexia
  47. Insight
  48. Intersect ENT
  49. Intravacc
  50. Iowa State University
  51. Janssen Pharmaceuticals
  52. Ji Xing Pharmaceuticals
  53. Kaléo
  54. Kindeva Drug Delivery
  55. Kleo Pharmaceuticals
  56. Kurve Technology
  57. Lachesis Biosciences
  58. Levo Therapeutics
  59. Lonza
  60. Medigen Vaccine Biologics
  61. Medline
  62. Menarini
  63. Mount Sinai Health System
  64. Mystic Pharmaceuticals
  65. Nanomerics
  66. Nanopharm
  67. Nasus Pharma
  68. Nemera
  69. Neurelis
  70. Neuronasal
  71. Noveome Biotherapeutics
  72. Odyssey Group International
  73. Olfax Medical
  74. Opiant Pharmaceuticals
  75. Optinose
  76. Orexo
  77. Oyster Point Pharma
  78. PaxMedica
  79. Phil
  80. Provectus Biopharmaceuticals
  81. Recordati
  82. Recro Pharma
  83. Rocket Science Health
  84. SaNOtize Research and Development
  85. Seelos Therapeutics
  86. Seqirus
  87. Seurat Therapeutics
  88. Singota Solutions
  89. Sinus Dynamics
  90. SipNose
  91. SNBL
  92. Sorrento Therapeutics
  93. Sosei Heptares
  94. Summit Biosciences
  95. Teleflex
  96. National Institutes of Health
  97. The University of Tennessee Health Science Center
  98. Tian Medical
  99. Tiziana Life Sciences
  100. UCB
  101. Univercells
  102. University of Calgary
  103. University of Massachusetts
  104. University of Oxford
  105. Utrecht University
  106. Valois
  107. Veeva Systems
  108. Vigene Biosciences
  109. Virpax Pharmaceuticals
  110. Wageningen Bioveterinary Research
  111. Yuhan Corporation
  112. Zeteo Biomedical

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com